Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of MK-3120 in advanced solid tumors
MOH_2025-02-16_013778Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MK-3120 in transitional cell carcinoma (TCC), head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC) and 2 more (6 cohorts), sponsored by Merck & Co. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
MK-3120
03
Conditions
transitional cell carcinoma (TCC)head and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)endometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on MOH_2025-02-16_013778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013778.